Peak Bio (NASDAQ:PKBO – Get Free Report) and Avalon GloboCare (NASDAQ:ALBT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.
Risk & Volatility
Peak Bio has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.
Insider and Institutional Ownership
1.2% of Avalon GloboCare shares are held by institutional investors. 19.9% of Peak Bio shares are held by company insiders. Comparatively, 64.0% of Avalon GloboCare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Peak Bio and Avalon GloboCare’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Peak Bio||$610,000.00||2.96||-$13.09 million||N/A||N/A|
|Avalon GloboCare||$1.20 million||5.45||-$11.93 million||N/A||N/A|
Avalon GloboCare has higher revenue and earnings than Peak Bio.
This is a summary of current recommendations and price targets for Peak Bio and Avalon GloboCare, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Avalon GloboCare beats Peak Bio on 7 of the 9 factors compared between the two stocks.
About Peak Bio
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.
About Avalon GloboCare
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.
Receive News & Ratings for Peak Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peak Bio and related companies with MarketBeat.com's FREE daily email newsletter.